Market Tracker

09/30 12:58pm ET

PDL BioPharma Inc (NASDAQ:PDLI)

3.33
Delayed Data
As of 12:42pm ET
 +0.10 / +3.10%
Today’s Change
2.58
Today|||52-Week Range
5.35
-5.93%
Year-to-Date
ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan
10:54am / Zacks.com - Paid Partner Content
Will PDL BioPharma (PDLI) Continue to Surge Higher?
Sep 20 / Zacks.com - Paid Partner Content
The Highest-Yielding Drug Stocks
Sep 29 / MotleyFool.com - Paid Partner Content
Forget Novavax, Buy These 4 Biotech Stocks Instead
Sep 16 / Zacks.com - Paid Partner Content
When You Should (and Shouldnt) Panic Over Earnings Results
Sep 28 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close3.23
Today’s open3.23
Day’s range3.21 - 3.34
Volume525,843
Average volume (3 months)1,444,792
Market cap$534.7M
Dividend yield6.01%
Data as of 12:42pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)+9.14%
Earnings growth (this year)-74.67%
Earnings growth (next 5 years)+17.00%
Revenue growth (last year)+0.01%
P/E ratio2.4
Price/Sales0.99
Price/Book0.76

Competitors

 Today’s
change
Today’s
% change
BLCMBellicum Pharmaceuti...+0.10+0.50%
MCRBSeres Therapeutics I...-0.30-2.37%
EPZMEpizyme Inc+0.27+2.84%
ADAPAdaptimmune Therapeu...+0.01+0.14%
Data as of 12:57pm ET, 09/30/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)$0.08
Annual revenue (last year)$585.1M
Annual profit (last year)$332.8M
Net profit margin56.88%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John Peter McLaughlin
Chief Financial Officer &
Vice President
Peter S. Garcia
Corporate headquarters
Incline Village, Nevada

Forecasts